DNAPrint Genomics

DNAPrint Genomics OpEx/Revenue

The Operating Expenses to Revenue Ratio of DNAPrint Genomics (DNAG) as of Nov 7, 2026 is 395.45 %.

OpEx/Revenue

395.45 %

Last updated:

Operating Expenses to Revenue Ratio of DNAPrint Genomics is 2006 395.45 % . Operating Expenses to Revenue Ratio of DNAPrint Genomics was 2005 - . It decreases by % lower compared to the previous year.

The DNAPrint Genomics OpEx/Revenue history

The DNAPrint Genomics OpEx/Revenue history
YEAROpEx/RevenueYoY
395.45 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

DNAPrint Genomics Stock analysis

What does DNAPrint Genomics do? DNAPrint Genomics Inc. was an American company specializing in researching genetic differences and their impact on health, diagnostics, and forensic applications. Founded in Sarasota, Florida in 1997, originally named Genaissance Pharmaceuticals, the company focused on medical research. In 2005, it changed its name to DNAPrint Genomics and shifted its focus to genetic testing development. The company's business model included developing and marketing molecular tests that can reveal an individual's genetic background, providing access to new markets and customers. DNAPrint Genomics offered various product lines for disease diagnosis, including tests for identifying and diagnosing specific diseases like breast cancer, colon cancer, and Alzheimer's. They also provided diagnostics for personalized medicine, matching medication to individuals' genetic predispositions. However, the company gained attention primarily for its forensic applications. They developed a system called DNAWitness, allowing comparison of unknown DNA samples with DNA databases to create offender profiles. The system was used by law enforcement agencies in the U.S. to aid crime investigation and was also involved in international police collaborations. DNAPrint Genomics pursued patents and partnerships with other companies to expand access to new technologies and developments, aiming to position itself in the international market. In 2008, the company announced its discontinuation due to economic reasons, facing complications in selling its DNAWitness system and encountering difficulties in selling its diagnostic tests. Despite having promising products, the company was unable to stabilize its market position and become profitable. DNAPrint Genomics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about DNAPrint Genomics stock

Operating Expenses to Revenue Ratio of DNAPrint Genomics is 395.45 % in 2006.

On Eulerpool you can find the complete historical development of Operating Expenses to Revenue Ratio DNAPrint Genomics since 2006 – with annual values, charts, and detailed analysis.

The OpEx/Revenue ratio measures total operating expenses as a percentage of revenue. Declining ratios suggest improving operational leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Expenses to Revenue Ratio's DNAPrint Genomics with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Expenses to Revenue Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Expenses to Revenue Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — DNAPrint Genomics

All Key Metrics — DNAPrint Genomics